Global Point of Care Infectious Disease Testing Market Revenue Grows at a CAGR of 4.97%

Introduction

Straits Research released its highly anticipated report, “Global Point of Care Infectious Disease Testing Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 13.83 billion in 2025 and is anticipated to grow to USD 21.32 billion by 2034, growing at a CAGR of 4.97% from 2026-2034.

Market Dynamics

The growth of the point-of-care infectious disease testing market is primarily driven by the increasing global burden of infectious diseases and the rising adoption of decentralized diagnostic models aimed at early detection and containment. The growing emphasis on preventive healthcare, coupled with government-led screening programs and the availability of portable molecular testing devices, is accelerating the shift toward rapid, near-patient testing across hospitals, clinics, and community health settings. However, market expansion is restrained by variability in test performance across decentralized environments, where inconsistencies in sample collection, limited operator training, and a lack of standardized validation protocols can affect diagnostic accuracy and clinical reliability. Despite these challenges, the market presents a strong opportunity in the integration of POC diagnostics with digital health ecosystems and telemedicine platforms, enabling remote result interpretation, real-time disease surveillance, and improved patient engagement through connected and data-driven healthcare solutions.

Market Highlights

• By Product, the consumables segment dominated the market in 2025, accounting for 70.12% of the total share.
• By Technology, the molecular diagnostics segment led the market with a revenue share of 46.78% in 2025.
• Based on Application, the respiratory infection testing products segment dominated the market with a 32.34% revenue share in 2025.
• Based on End Use, the hospital segment held the dominant share of 37.68% in 2025.
• Regional Insights: North America dominated the market with more than 47% of market share in 2025, driven by the widespread availability of advanced diagnostic infrastructure, strong adoption of molecular point-of-care platforms, and supportive regulatory frameworks that encourage rapid product approvals and clinical implementation.

Competitive Players

1. Abbott
2. Hoffmann-La Roche Ltd 
3. Thermo Fisher Scientific Inc.
4. Siemens Healthineers AG
5. BD
6. Chembio Diagnostics, Inc.
7. Trinity Biotech
8. Cardinal Health
9. Quest Diagnostics
10. Bio-Rad Laboratories, Inc.
11. BIOMÉRIEUX SA
12. Trivitron Healthcare
13. QuidelOrtho Corporation
14. Cepheid
15. Hologic, Inc
16. OraSure Technologies Inc.
17. EKF Diagnostics Holdings plc.
18. Others

Recent Developments

October 2025: A research team led by Imperial College London developed a new low-cost, rapid diagnostic test called Dragonfly that detects asymptomatic cases of malaria from a simple finger-prick blood sample.

Segmentation

1. By Product (2026-2034)
   1. Consumables
   2. Instruments
   3. Software and Services
2. By Technology (2026-2034)
   1. Lateral Flow Immunoassay
   2. Agglutination Test
   3. Flow-through test/ Immunoconcentration Assay
   4. Molecular Diagnostics
   5. Others
3. By Application (2026-2034)
   1. Respiratory Infection Testing Products
      1. Influenza testing products
      2. Tuberculosis
      3. Other respiratory infection testing products
   2. Healthcare-Associated Infection Testing Products
   3. Tropical Disease Testing Products
   4. Sexually Transmitted Disease Testing Products
      1. HIV testing products
      2. Hepatitis testing products
      3. Syphilis testing products
      4. Human papillomavirus testing products
4. By End Use (2026-2034)
   1. Hospital
   2. Diagnostic Laboratories
   3. Home-care settings
   4. Others